Johnson & Johnson (JNJ) has announced promising results from its Phase 1b/2 OrigAMI-4 study, which tested subcutaneous amivantamab combined with hyaluronidase-lpuj in patients with advanced head and neck squamous cell carcinoma. The treatment demonstrated a confirmed overall response rate of 42%, with over one-third of responders achieving complete responses. Notably, the median duration of response remains unreported after an 11.8-month follow-up.
This development is significant for JNJ as it seeks FDA approval for the therapy, having already received Breakthrough Therapy Designation. The potential approval could enhance JNJ’s oncology portfolio and impact stock performance positively, particularly if the treatment gains traction in a market that increasingly values innovative cancer therapies.
Market professionals should monitor the FDA’s response to the supplemental Biologics License Application (sBLA), as successful approval could bolster investor confidence and influence JNJ’s share price trajectory in the oncology sector.
Source: nasdaq.com